Two-drug combination before surgery benefits women with triple-negative breast cancer

[News]

A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer.

More... (http://www.news-medical.net/news/20141215/Two-drug-combination-before-surgery-benefits-women-with-triple-negative-breast-cancer.aspx)